Titre : Syndécane-3

Syndécane-3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Multicenter Studies as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Syndécane-3 : Questions médicales les plus fréquentes", "headline": "Syndécane-3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Syndécane-3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-30", "dateModified": "2025-04-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Syndécane-3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Syndécanes", "url": "https://questionsmedicales.fr/mesh/D053667", "about": { "@type": "MedicalCondition", "name": "Syndécanes", "code": { "@type": "MedicalCode", "code": "D053667", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.847" } } }, "about": { "@type": "MedicalCondition", "name": "Syndécane-3", "alternateName": "Syndecan-3", "code": { "@type": "MedicalCode", "code": "D053670", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Addolorata Pisconti", "url": "https://questionsmedicales.fr/author/Addolorata%20Pisconti", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, IIB, University of Liverpool, Liverpool, UK." } }, { "@type": "Person", "name": "Martin Götte", "url": "https://questionsmedicales.fr/author/Martin%20G%C3%B6tte", "affiliation": { "@type": "Organization", "name": "Department of Gynecology and Obstetrics, Münster University Hospital, Albert-Schweitzer-Campus 1, D11, 48149 Muenster, Germany." } }, { "@type": "Person", "name": "Ilona Kovalszky", "url": "https://questionsmedicales.fr/author/Ilona%20Kovalszky", "affiliation": { "@type": "Organization", "name": "Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary." } }, { "@type": "Person", "name": "Samantha Arokiasamy", "url": "https://questionsmedicales.fr/author/Samantha%20Arokiasamy", "affiliation": { "@type": "Organization", "name": "Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom." } }, { "@type": "Person", "name": "James R Whiteford", "url": "https://questionsmedicales.fr/author/James%20R%20Whiteford", "affiliation": { "@type": "Organization", "name": "Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Optical enhancement mode 2 improves the detection rate of gastric neoplastic lesion in high-risk populations: A multicenter randomized controlled clinical study.", "datePublished": "2024-05-16", "url": "https://questionsmedicales.fr/article/38753528", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ueg2.12577" } }, { "@type": "ScholarlyArticle", "name": "Tumor Location Is an Independent Prognostic Factor in Completely Resected Pathological Stage I Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.", "datePublished": "2024-04-27", "url": "https://questionsmedicales.fr/article/38730661", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cancers16091710" } }, { "@type": "ScholarlyArticle", "name": "Using the geriatric nutritional risk index to predict outcomes in older patients with remnant gastric cancer after gastrectomy: a retrospective multicenter study in Japan.", "datePublished": "2024-04-23", "url": "https://questionsmedicales.fr/article/38652300", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00595-024-02850-w" } }, { "@type": "ScholarlyArticle", "name": "Holistic assessment of cochlear implant outcomes using the international classification of functioning disability and health model: data analysis of a longitudinal prospective multicenter study.", "datePublished": "2024-04-04", "url": "https://questionsmedicales.fr/article/38573516", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00405-024-08600-5" } }, { "@type": "ScholarlyArticle", "name": "The Sensitivity of Limited-Sequence MRI in Identifying Pediatric Cervical Spine Injury: A Western Pediatric Surgery Research Consortium Multicenter Retrospective Cohort Study.", "datePublished": "2024-03-25", "url": "https://questionsmedicales.fr/article/38523120", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/TA.0000000000004271" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Glycoprotéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008562" }, { "@type": "ListItem", "position": 6, "name": "Syndécanes", "item": "https://questionsmedicales.fr/mesh/D053667" }, { "@type": "ListItem", "position": 7, "name": "Syndécane-3", "item": "https://questionsmedicales.fr/mesh/D053670" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Syndécane-3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Syndécane-3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Syndécane-3", "description": "Comment diagnostiquer une anomalie du syndécane-3 ?\nQuels examens sont utilisés pour évaluer le syndécane-3 ?\nLe dosage sanguin peut-il aider au diagnostic ?\nQuels marqueurs sont associés au syndécane-3 ?\nLe diagnostic est-il difficile à établir ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Syndécane-3", "description": "Quels symptômes sont liés à une dysfonction du syndécane-3 ?\nLe syndécane-3 est-il lié à des maladies spécifiques ?\nPeut-on observer des symptômes cutanés ?\nY a-t-il des symptômes systémiques associés ?\nLes symptômes varient-ils d'un patient à l'autre ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Syndécane-3", "description": "Peut-on prévenir les dysfonctionnements du syndécane-3 ?\nY a-t-il des facteurs de risque connus ?\nDes dépistages réguliers sont-ils recommandés ?\nL'alimentation influence-t-elle le syndécane-3 ?\nLe stress a-t-il un impact sur le syndécane-3 ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Syndécane-3", "description": "Quels traitements ciblent le syndécane-3 ?\nLe traitement est-il efficace ?\nY a-t-il des effets secondaires des traitements ?\nDes traitements expérimentaux existent-ils ?\nLe suivi est-il nécessaire après traitement ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Syndécane-3", "description": "Quelles complications peuvent survenir avec le syndécane-3 ?\nLe syndécane-3 est-il lié à des complications cardiovasculaires ?\nDes complications neurologiques sont-elles possibles ?\nComment gérer les complications liées au syndécane-3 ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Syndécane-3", "description": "Quels sont les principaux facteurs de risque ?\nLe mode de vie influence-t-il les risques ?\nLes infections jouent-elles un rôle ?\nY a-t-il un lien avec l'obésité ?\nLes facteurs environnementaux sont-ils significatifs ?", "url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie du syndécane-3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests génétiques et des analyses de tissus pour évaluer l'expression du syndécane-3." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer le syndécane-3 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des biopsies et des analyses immunohistochimiques peuvent être réalisées pour évaluer le syndécane-3." } }, { "@type": "Question", "name": "Le dosage sanguin peut-il aider au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de dosage sanguin standardisé pour le syndécane-3." } }, { "@type": "Question", "name": "Quels marqueurs sont associés au syndécane-3 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs tumoraux et des cytokines peuvent être associés à l'expression du syndécane-3." } }, { "@type": "Question", "name": "Le diagnostic est-il difficile à établir ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diagnostic peut être complexe en raison de la variabilité de l'expression du syndécane-3." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une dysfonction du syndécane-3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des troubles de l'adhésion cellulaire et des anomalies tissulaires." } }, { "@type": "Question", "name": "Le syndécane-3 est-il lié à des maladies spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est impliqué dans des maladies comme le cancer et les maladies inflammatoires." } }, { "@type": "Question", "name": "Peut-on observer des symptômes cutanés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies cutanées peuvent survenir en raison de l'implication du syndécane-3 dans la peau." } }, { "@type": "Question", "name": "Y a-t-il des symptômes systémiques associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes systémiques comme la fatigue et la douleur peuvent être observés dans certains cas." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'un patient à l'autre ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier considérablement selon l'individu et la pathologie associée." } }, { "@type": "Question", "name": "Peut-on prévenir les dysfonctionnements du syndécane-3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire certains risques associés." } }, { "@type": "Question", "name": "Y a-t-il des facteurs de risque connus ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs comme l'inflammation chronique et des prédispositions génétiques sont identifiés." } }, { "@type": "Question", "name": "Des dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des dépistages peuvent être recommandés pour les personnes à risque élevé de maladies associées." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le syndécane-3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut influencer positivement l'expression du syndécane-3." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur le syndécane-3 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut affecter l'expression du syndécane-3 et contribuer à des maladies." } }, { "@type": "Question", "name": "Quels traitements ciblent le syndécane-3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées et des anticorps monoclonaux peuvent être utilisés pour cibler le syndécane-3." } }, { "@type": "Question", "name": "Le traitement est-il efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité du traitement dépend de la pathologie et de l'expression du syndécane-3." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent entraîner des effets secondaires comme des réactions immunitaires." } }, { "@type": "Question", "name": "Des traitements expérimentaux existent-ils ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements expérimentaux sont en cours d'évaluation pour cibler le syndécane-3." } }, { "@type": "Question", "name": "Le suivi est-il nécessaire après traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour évaluer la réponse au traitement et ajuster si nécessaire." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le syndécane-3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des métastases tumorales et des troubles immunitaires peuvent survenir." } }, { "@type": "Question", "name": "Le syndécane-3 est-il lié à des complications cardiovasculaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études suggèrent un lien entre le syndécane-3 et des complications cardiovasculaires." } }, { "@type": "Question", "name": "Des complications neurologiques sont-elles possibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines recherches indiquent que des complications neurologiques peuvent être associées." } }, { "@type": "Question", "name": "Comment gérer les complications liées au syndécane-3 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, les antécédents familiaux et les maladies inflammatoires." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il les risques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques." } }, { "@type": "Question", "name": "Les infections jouent-elles un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections chroniques peuvent augmenter le risque de dysfonction du syndécane-3." } }, { "@type": "Question", "name": "Y a-t-il un lien avec l'obésité ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'obésité est un facteur de risque reconnu pour des dysfonctionnements associés au syndécane-3." } }, { "@type": "Question", "name": "Les facteurs environnementaux sont-ils significatifs ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des polluants environnementaux peut influencer l'expression du syndécane-3." } } ] } ] }

Sources (10000 au total)

Optical enhancement mode 2 improves the detection rate of gastric neoplastic lesion in high-risk populations: A multicenter randomized controlled clinical study.

Detection of early neoplastic lesions is crucial for improving the survival rates of patients with gastric cancer. Optical enhancement mode 2 is a new image-enhanced endoscopic technique that offers b... In this prospective multicenter randomized controlled trial, patients were randomly assigned to optical enhancement mode 2 or WLI groups. Detection of suspicious neoplastic lesions during the examinat... A total of 1211 and 1219 individuals were included in the optical enhancement mode 2 and WLI groups, respectively. The detection rate of neoplastic lesions was significantly higher in the optical enha... Optical enhancement mode 2 was more effective than WLI for detecting neoplastic lesions in the stomach, and can serve as a new method for screening early gastric cancer in clinical practice.... United States National Library of Medicine (https://www.... gov), ID: NCT040720521....

Using the geriatric nutritional risk index to predict outcomes in older patients with remnant gastric cancer after gastrectomy: a retrospective multicenter study in Japan.

This study investigated the prognostic value of the geriatric nutritional risk index (GNRI) in patients undergoing curative gastrectomy for remnant gastric cancer (RGC).... This multicenter retrospective study included 105 patients with RGC of ≥ 65 years of age who underwent curative gastrectomy at 10 institutions in Japan between January 2000 and December 2016. Postoper... Receiver operating curve analyses indicated that the optimal cutoff value of the GNRI for OS was 95.4. Patients were categorized into high and low GNRI groups based on the optimal GNRI cutoff value. T... The GNRI is a promising predictor of both short- and long-term outcomes in older patients with RGC....

Holistic assessment of cochlear implant outcomes using the international classification of functioning disability and health model: data analysis of a longitudinal prospective multicenter study.

To study outcome after cochlear implantation using the Cochlear Implant (CI) outcome assessment protocol based on the International Classification of Functioning, Disability and Health (ICF) model (CI... Raw data of a prospective, longitudinal, multicenter study was analyzed. Seventy-two CI candidates were assessed preoperatively and six months postoperatively using the CI-ICF protocol. Following tool... There was a significant improvement of speech discrimination in quiet (p = 0.015; p < 0.001) and in noise (p = 0.041; p < 0.001), sound detection (p < 0.001), tinnitus (p = 0.026), listening (p < 0.00... This study highlights the positive impact of cochlear implantation on auditory performance, communication, and subjective well-being. The CI-ICF protocol provides a holistic and comprehensive view of ...

The Sensitivity of Limited-Sequence MRI in Identifying Pediatric Cervical Spine Injury: A Western Pediatric Surgery Research Consortium Multicenter Retrospective Cohort Study.

Clinical clearance of a child's cervical spine after trauma is often challenging due to impaired mental status or an unreliable neurologic examination. Magnetic resonance imaging (MRI) is the gold sta... We conducted a ten-center, five-year retrospective cohort study (2017-2021) of all children (0-18y) with a cervical spine MRI after blunt trauma. MRI images were re-reviewed by a study pediatric radio... We identified 2,663 children less than 18 years of age who underwent an MRI of the cervical spine with 1,008 injuries detected on full-sequence studies. The sensitivity and negative predictive value o... LSMRI is reliably detects clinically significant ligamentous injury in children after blunt trauma. To decrease anesthesia use and minimize MRI time, trauma centers should develop LSMRI screening prot... 2 (Diagnostic Tests or Criteria)....

Novel β-lactam-β-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort study.

Data comparing the clinical outcomes of novel β-lactam-β-lactamase inhibitors given in combination versus monotherapy for the treatment of multidrug-resistant (MDR) P. aeruginosa infections are lackin... This retrospective cohort study included patients who received novel β-lactam-β-lactamase inhibitors as monotherapy or in combination for the treatment of MDR P. aeruginosa infections. The study was c... 118 patients and 82 patients were included in monotherapy and combination therapy arms, respectively. The cohort represented an ill population with 56% in the intensive care unit and 37% in septic sho... Novel β-lactam-β-lactamase inhibitors when used in combination with other antibiotics did not add clinical benefit compared to their use as monotherapy in the treatment of MDR P. aeruginosa infections...

One-stage versus two-stage endoscopic management for acute cholangitis caused by common bile duct stones: A retrospective multicenter cohort study.

One-stage endoscopic management, where papillary interventions and stone removal are simultaneously performed, has been reported to be an effective treatment for acute cholangitis caused by common bil... We retrospectively studied 577 patients who underwent one- or two-stage endoscopic management for acute cholangitis between May 2010 and December 2020. The patients were divided into one- and two-stag... The technical and clinical success were similar in both groups, although the length of hospital stay was significantly shorter in the one-stage group. Although there was no difference in the early adv... Although one-stage endoscopic management is useful and safe with reducing hospital stays, diligent postoperative follow-up with consideration to recurrence of CBDS is essential....

Bilateral Endoscopic debridement combined with local antituberculosis drugs for Thoracic Tuberculosis with large Paravertebral abscess: A Multicenter study with 4-year follow-up.

Paravertebral abscess represents a prevalent manifestation of thoracic tuberculosis, often necessitating surgical intervention. In this study, we introduced a novel approach by employing bilateral end... We conducted a retrospective analysis on patients diagnosed with thoracic tuberculosis and paravertebral abscess (TB-PA) who underwent bilateral endoscopic debridement combined with local antitubercul... The surgical procedures were successfully completed for all subjects, with an average intraoperative bleeding volume of (25.2 ± 8.9) ml, an average surgical time of (68.4 ± 14.0) minutes, an average f... The application of BED+LAD in the treatment of TB-PA proved to be a safe, effective, and feasible approach....

Does Early and Late Weight Bearing Have an Effect on the Results of Elderly Tibial Plateau Fractures with Internal Fixation?: A Multicenter (TRON Group) Study.

There is still no consensus on the length of the non-bearing period required for tibial plateau fractures (TPFs) treated surgically. Several studies showed that full weight bearing immediately postope... We extracted the data of 432 patients who suffered TPF from January 2011 to December 2020 from a database which is named TRON. We excluded patients with insufficient follow-up postoperatively, AO type... There were no significant statistical differences between the EWB group and NWB group after matching. The mean follow-up period was 28.0 (range 12-73) months. All cases did not require reoperation or ... We found that early weight bearing could contribute to increased condylar widening. While our short-term follow-up didn't reveal any significant clinical differences, this highlights the need for long...

Long-term outcomes of the pentaspline pulsed field ablation catheter for the treatment of paroxysmal atrial fibrillation: Results of the prospective, multicenter FARA-Freedom Study.

Pulmonary vein isolation (PVI) is well-established strategy for the treatment of paroxysmal atrial fibrillation (PAF). Despite randomized controlled trials and real-world data showing the promise of p... FARA-Freedom, a prospective, non-randomized, multicenter study, enrolled patients with PAF undergoing de novo PVI with PFA, which were followed for 12 months with weekly transtelephonic monitoring (TT... The study enrolled 179 PAF patients (62 ± 10 yr, 39% female) at 13 centers. At index procedure, all PVs were successfully isolated with the pentaspline PFA catheter. Procedure and left atrial dwell ti... In this prospective, non-randomized, multicenter study, PVI using a pentaspline PFA catheter was effective in treating PAF patients despite rigorous endpoint definitions and high monitoring compliance...